M S Kaminski

Summary

Affiliation: University of Michigan
Country: USA

Publications

  1. ncbi Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma
    M S Kaminski
    Department of Internal Medicine, University of Michigan, Ann Arbor 48109 0724, USA
    J Clin Oncol 14:1974-81. 1996
  2. ncbi Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience
    M S Kaminski
    Division of Hematology Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109 0936, USA
    Blood 96:1259-66. 2000
  3. ncbi Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas
    M S Kaminski
    University of Michigan Medical Center, Ann Arbor, MI 48109 0936, USA
    J Clin Oncol 19:3918-28. 2001
  4. ncbi 131I-tositumomab therapy as initial treatment for follicular lymphoma
    Mark S Kaminski
    Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan Medical Center, Ann Arbor, MI 48109 0936, USA
    N Engl J Med 352:441-9. 2005
  5. ncbi Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab
    Mark S Kaminski
    University of Michigan Comprehensive Cancer Center, Ann Arbor, USA
    J Clin Oncol 23:7985-93. 2005
  6. ncbi I-131 anti-B1 therapy/tracer uptake ratio using a new procedure for fusion of tracer images to computed tomography images
    K F Koral
    Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor 48109 0552, USA
    Clin Cancer Res 5:3004s-3009s. 1999
  7. ncbi Tumor-absorbed-dose estimates versus response in tositumomab therapy of previously untreated patients with follicular non-Hodgkin's lymphoma: preliminary report
    K F Koral
    Univ of Michigan Med Center, Ann Arbor 48109 0552, USA
    Cancer Biother Radiopharm 15:347-55. 2000
  8. ncbi Radioimmunotherapy with iodine-131 tositumomab in patients with low-grade non-Hodgkin's B-cell lymphoma does not induce loss of acquired humoral immunity against common antigens
    T Nordøy
    Department of Oncology, University Hospital of Tromsø, Tromsø, N 9038, Norway
    Clin Immunol 100:40-8. 2001

Collaborators

Detail Information

Publications8

  1. ncbi Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma
    M S Kaminski
    Department of Internal Medicine, University of Michigan, Ann Arbor 48109 0724, USA
    J Clin Oncol 14:1974-81. 1996
    ....
  2. ncbi Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience
    M S Kaminski
    Division of Hematology Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109 0936, USA
    Blood 96:1259-66. 2000
    ..A single, well-tolerated treatment with iodine (131)I tositumomab can, therefore, produce frequent and durable responses in NHL, especially low-grade or transformed NHL. (Blood. 2000;96:1259-1266)..
  3. ncbi Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas
    M S Kaminski
    University of Michigan Medical Center, Ann Arbor, MI 48109 0936, USA
    J Clin Oncol 19:3918-28. 2001
    ....
  4. ncbi 131I-tositumomab therapy as initial treatment for follicular lymphoma
    Mark S Kaminski
    Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan Medical Center, Ann Arbor, MI 48109 0936, USA
    N Engl J Med 352:441-9. 2005
    ..Anti-CD20 radioimmunotherapy is effective in patients who have had a relapse after chemotherapy or who have refractory follicular lymphoma, but it has not been tested in previously untreated patients...
  5. ncbi Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab
    Mark S Kaminski
    University of Michigan Comprehensive Cancer Center, Ann Arbor, USA
    J Clin Oncol 23:7985-93. 2005
    ..To study efficacy and safety of re-treatment with I-131 tositumomab in patients with low-grade, follicular, or transformed low-grade B-cell lymphoma who relapsed following a response to I-131 tositumomab...
  6. ncbi I-131 anti-B1 therapy/tracer uptake ratio using a new procedure for fusion of tracer images to computed tomography images
    K F Koral
    Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor 48109 0552, USA
    Clin Cancer Res 5:3004s-3009s. 1999
    ..For greater accuracy with individual tumors, however, an intratherapy evaluation is probably necessary because the range of R is large...
  7. ncbi Tumor-absorbed-dose estimates versus response in tositumomab therapy of previously untreated patients with follicular non-Hodgkin's lymphoma: preliminary report
    K F Koral
    Univ of Michigan Med Center, Ann Arbor 48109 0552, USA
    Cancer Biother Radiopharm 15:347-55. 2000
    ..In conclusion, there was a trend toward a significant difference in the radiation dose between CR and PR patients, but it was only moderately predictive of response...
  8. ncbi Radioimmunotherapy with iodine-131 tositumomab in patients with low-grade non-Hodgkin's B-cell lymphoma does not induce loss of acquired humoral immunity against common antigens
    T Nordøy
    Department of Oncology, University Hospital of Tromsø, Tromsø, N 9038, Norway
    Clin Immunol 100:40-8. 2001
    ..No significant reduction in antibody concentrations to tetanus or measles could be detected. The data show that acquired humoral immunity against common antigens appears to be preserved despite a temporary loss of B-lymphocytes...